RemedyRepack Recalls Ranitidine Tablets Due to Potential NDMA Contamination
RemedyRepack Inc. is recalling specific lots of Ranitidine 150 mg tablets because the supplier reported potential Nitrosodimethylamine (NDMA) levels above established limits.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric, particularly given the potential for significant health risks associated with NDMA contamination.
Plain-English summary
RemedyRepack Inc. is recalling 4,486 tablets of Ranitidine 150 mg. The recall is due to a Current Good Manufacturing Practice (CGMP) deviation and a notice from the supplier indicating potential Nitrosodimethylamine (NDMA) amounts above established levels.
The affected product is identified by Original Supplier's NDC 65162-0253-10 and Remedy Repackaged NDC 70518-1714-00. The specific lots subject to recall are J0376034-052319 (exp. 05/2020), J0406133-093019 (exp. 10/2020), J038005-082719 (exp. 08/2020), J0390280-072519 (exp. 07/2020), J0390277-072519 (exp. 07/2020), and J0349352-012519 (exp. 01/2020).
The product was distributed to two facilities in California and New York. Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates. If the product is found, it should be returned to the source or disposed of according to local regulations.
The recalled product
- Product
- Ranitidine 150 mg tablet Original Supplier's NDC 65162-0253-10 Remedy Repackaged NDC 70518-1714-00
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 4,486
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #: J0376034-052319
- exp. date 05/2020 Lot #: J0406133-093019
- exp. date 10/2020 Lot #: J038005-082719
- exp. date 08/2020 Lot #: J0390280-072519
- exp. date 07/2020 Lot #: J0390277-072519
- exp. date 07/2020 Lot #: J0349352-012519
- exp. date 01/2020
Distribution
Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · ndma contamination
See all →- SevereMetformin Hydrochloride Extended-Release Tablets Recalled for NDMA Contamination
FDA (Drugs) · 2022-02-02
- ModerateMetformin 750 mg Extended Release Recalled for NDMA Contamination
FDA (Drugs) · 2022-01-19
- HighMetformin Hydrochloride Tablets Recalled for NDMA Contamination
FDA (Drugs) · 2021-06-30
- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-11-25
- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-07-08